Capsules or Tablets? A Guide for Supplement Brands

Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

When it comes to deciding between capsules and tablets, supplement brands need to balance production costs, formulation requirements and consumer preferences. Selecting the correct form of delivery directly impacts a product’s market viability, shelf life and profitability. Before launching or expanding a dietary or supplementary line, brands are faced with the pivotal decision of whether […]

The post Capsules or Tablets? A Guide for Supplement Brands appeared first on Medical News Bulletin.

New DNA Test for Inherited Muscle Diseases And More

Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

What do you do when there is clearly something wrong with your child, but the standard diagnostic tests keep showing up negative? New advances in DNA testing might be about to bring answers and improved care for people living with inherited muscle diseases. Australian scientists have developed a more reliable diagnostic DNA test for inherited […]

The post New DNA Test for Inherited Muscle Diseases And More appeared first on Medical News Bulletin.

Hospital length of stay falls after tele-ICU implementation

PHOENIX — Hospital length of stay fell by 1.7 days 18 months after vs. before tele-ICU implementation in four safety-net hospitals, according to data presented at the CHEST Annual Meeting.
“Tele-ICU is not simply a camera in a patient’s room. It is a model of care delivery,” Chidinma Chima-Melton, MD, MBA, FCCP, ATSF, founder and CEO of Tele-ICU Inc. and cardiopulmonary medical director at Pipeline Health, told Healio. “The technology connects us, but the clinical integration is what matters.”
In a retrospective cohort study, Chima-Melton and colleagues evaluated 6,386 ICU admissions from four

Quality of life improves in asthma with depemokimab

PHOENIX — Patients who used depemokimab for uncontrolled asthma experienced improved symptoms, activity, impact on daily life and well-being through 52 weeks, according to a poster presented at the CHEST Annual Meeting.
The biologic’s dosing schedule of twice a year may reduce the burden of treatment for patients, Ian D. Pavord, MA, DM, FRCP, FERS, FMedSci, professor of respiratory medicine at the University of Oxford, and colleagues wrote.
The 559 patients with a baseline Asthma Control Questionnaire-5 score of 1.5 or higher in the phase 3 SWIFT-1/-2 studies included 363 who used subcutaneous

Overlap between migraine, endometriosis larger than reported

SAN DIEGO — Women with endometriosis were 2.3 times more likely to have migraine compared with women who do not have endometriosis, and the comorbidity between the two conditions could be as high as 78%, according to a presenter.
The size of the overlap between the two conditions is likely underacknowledged, Yohannes Woubishet Woldeamanuel, MD, assistant professor of neurology at Mayo Clinic Arizona, said at the American Neurological Association’s 151st Annual Meeting.
Short-term health records, such as 1-year billing records, could be missing up to 90% of women who have overlapping migraine

Mirikizumab linked to clinical remission in pediatric UC

NASHVILLE, Tenn. — Among children with ulcerative colitis, mirikizumab achieved clinical and endoscopic remission rates exceeding those of historical adult outcomes with placebo at week 12, according to data presented.
Researchers also reported associations between mirikizumab (Omvoh, Eli Lilly & Co.) and clinical, symptomatic and endoscopic responses at this time point, as well as a reduction in fecal calprotectin levels.
“Simply put, we have very limited advanced therapy options for pediatric patients,” Marla C. Dubinsky, MD, chief of pediatric gastroenterology and nutrition at Mount

Proton pump inhibitor use linked to exacerbations in asthma

PHOENIX — Adults with asthma who used proton pump inhibitors had greater risks for exacerbations and other negative outcomes than those who did not, according to an abstract presented at the CHEST Annual Meeting.
However, the difference in mortality between patients who did or did not use proton pump inhibitors (PPIs) was not statistically significant, Joshua P. Le, MD, resident, Allegheny Health Network, and colleagues wrote.
Although some patients with nocturnal symptoms of asthma and coexisting reflux have benefited from PPI treatment, the researchers said, evidence for associations

Insulin resistance mediates link between premature menopause, CVD

Insulin resistance could mediate associations between premature menopause and higher CVD risk, according to research presented at The Menopause Society’s annual meeting.
Zailing Xing, PhD, an assistant professor at Florida A&M University and first author of the study, told Healio that premature menopause, when menopause occurs before age 40 years, “has been associated with an increased risk of CVD,” but “the mechanisms underlying this association remain unclear.”
“We wanted to better understand whether changes in glucose metabolism and insulin resistance might help explain this increased

CBT did not reduce postsurgical pain after extremity fracture

NASHVILLE, Tenn — Cognitive behavioral therapy did not significantly reduce moderate-to-severe persistent pain in patients recovering from extremity fracture surgery, according to results presented here.
“Our COPE trial did not find a significant difference between our app-based cognitive behavioral therapy program and usual care with regards to pain or any of our secondary outcomes,” Sheila A. Sprague, PhD, a clinical researcher and professor in the department of surgery at McMaster University in Hamilton, Ontario, said during a presentation at the Orthopaedic Trauma Association Annual

FDA approves first generic of Climara Pro hormone therapy patch

The FDA has approved a generic once-weekly transdermal hormone therapy patch for women with an intact uterus, according to a press release from the agency.
The approved HT patch (Zydus Pharmaceuticals) is the therapeutic equivalent of Climara Pro (Bayer) and is the first generic version approved by the FDA. Climara Pro consists of estradiol 0.045 mg per day and levonorgestrel 0.015 mg, and is approved in the U.S. for the treatment of moderate to severe vasomotor symptoms and for prevention of postmenopausal osteoporosis.
The generic transdermal system is specifically approved for women with an